Vistagen Presents Fasedienol Safety And Exploratory Efficacy Data From Phase 3 Open-Label Social Anxiety Disorder Study At American Society For Clinical Psychopharmacology Annual Meeting
Portfolio Pulse from Happy Mohamed
Vistagen (NASDAQ: VTGN) presented positive safety and exploratory efficacy data from its Phase 3 open-label study of fasedienol nasal spray for the treatment of anxiety in adults with social anxiety disorder at the American Society for Clinical Psychopharmacology Annual Meeting. The study showed favorable long-term treatment data from nearly 500 patients, suggesting that patient-tailored, as-needed administrations of fasedienol were safe and well-tolerated.
June 01, 2023 | 12:31 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Vistagen's positive Phase 3 data for fasedienol nasal spray in treating social anxiety disorder may boost investor confidence and potentially impact the stock price positively.
The positive Phase 3 data for Vistagen's fasedienol nasal spray indicates that the treatment is safe and well-tolerated, which may lead to increased investor confidence in the company's product pipeline and potential future revenues. This could result in a positive impact on the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100